1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Xinnate AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study TCP-25 gel, Vehicle (placebo) - Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa | Phase 2 | Recruiting | Xinnate AB | 32 | 2026-01-30 | 2026-10-22 |
| Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa. TCP-25 gel 0.86 mg/ml or placebo gel, TCP-25 gel 2.9 mg/ml or placebo gel, TCP-25 gel 8.6 mg/ml or placebo gel - Blister, Wound of Skin | Phase 1 | Completed | Xinnate AB | 35 | 2022-04-07 | 2024-03-26 |
Epidermolysis Bullosa (2) · Blister (1) · Epidermolysis Bullosa Dystrophica (1) · Epidermolysis Bullosa, Junctional (1)
Sweden (2) · France (1) · Greece (1) · Italy (1) · Poland (1) · Spain (1) · United States (1)